Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial
University of Oxford · Oxford BioMedica (United Kingdom) · +11 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
2,614
total citations
- FWCI
- 60.18
- Percentile
- 100%
- References
- 29
Citations per year
Authors
365- PMPedro M. FolegattiCorresponding
University of Oxford, Oxford BioMedica (United Kingdom), Jenner Institute
- KEKatie Ewer
University of Oxford, Oxford BioMedica (United Kingdom), Jenner Institute
- PKParvinder K. Aley
University of Oxford, Oxford BioMedica (United Kingdom)
- BABrian Angus
University of Oxford, Oxford BioMedica (United Kingdom)
- SBStephan Becker
Philipps University of Marburg
Topics & keywords
Topics
Keywords
- Reactogenicity
- Immunogenicity
- Medicine
- Vaccination
- Neutralization
- Virology
- Plaque reduction neutralization test
- Vaccination schedule
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.
Funding
- URUK Research and InnovationAward: MC_PC_19055
- CFCoalition for Epidemic Preparedness Innovations
- NINational Institute for Health and Care ResearchAward: MC_PC_19055
- UOUniversity of Oxford
- PIPirbright Institute
- OUOxford University Hospitals NHS Foundation Trust
- OHOxford Health NHS Foundation Trust
- MRMedical Research CouncilAward: MR/T001151/1
- EAEngineering and Physical Sciences Research CouncilAwards: EP/R013756/1, EP/R013756/1
- BABiotechnology and Biological Sciences Research CouncilAward: BB/S007911/1